13.57
Schlusskurs vom Vortag:
$12.31
Offen:
$13.5
24-Stunden-Volumen:
2.51M
Relative Volume:
3.71
Marktkapitalisierung:
$740.88M
Einnahmen:
$8.78M
Nettoeinkommen (Verlust:
$-104.70M
KGV:
-5.7257
EPS:
-2.37
Netto-Cashflow:
$-82.68M
1W Leistung:
+15.49%
1M Leistung:
+17.18%
6M Leistung:
+35.43%
1J Leistung:
-10.43%
Stoke Therapeutics Inc Stock (STOK) Company Profile
Firmenname
Stoke Therapeutics Inc
Sektor
Branche
Telefon
781-430-8200
Adresse
45 WIGGINS AVENUE, BEDFORD, MA
Vergleichen Sie STOK mit anderen Aktien
Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
---|---|---|---|---|---|---|
![]()
STOK
Stoke Therapeutics Inc
|
13.57 | 641.51M | 8.78M | -104.70M | -82.68M | -2.37 |
![]()
VRTX
Vertex Pharmaceuticals Inc
|
470.13 | 119.21B | 11.10B | -988.90M | -1.26B | -3.92 |
![]()
REGN
Regeneron Pharmaceuticals Inc
|
560.93 | 59.16B | 14.09B | 4.50B | 2.96B | 39.28 |
![]()
ALNY
Alnylam Pharmaceuticals Inc
|
325.28 | 40.57B | 2.35B | -269.70M | -75.39M | -2.09 |
![]()
ARGX
Argen X Se Adr
|
571.23 | 34.02B | 2.58B | 1.06B | -1.28B | 16.33 |
![]()
ONC
Beone Medicines Ltd Adr
|
295.59 | 29.19B | 3.81B | -644.79M | -669.77M | -6.24 |
Stoke Therapeutics Inc Stock (STOK) Upgrades & Downgrades
Datum | Aktion | Analytiker | Ratingänderung |
---|---|---|---|
2025-07-18 | Eingeleitet | Jefferies | Buy |
2024-12-20 | Eingeleitet | Chardan Capital Markets | Buy |
2024-10-14 | Fortgesetzt | Leerink Partners | Outperform |
2024-03-26 | Hochstufung | TD Cowen | Market Perform → Outperform |
2023-11-20 | Fortgesetzt | JP Morgan | Neutral |
2023-07-25 | Herabstufung | TD Cowen | Outperform → Market Perform |
2023-05-01 | Hochstufung | BofA Securities | Underperform → Neutral |
2023-04-26 | Fortgesetzt | Canaccord Genuity | Buy |
2023-01-06 | Herabstufung | BofA Securities | Buy → Underperform |
2022-10-24 | Hochstufung | SVB Leerink | Mkt Perform → Outperform |
2022-01-31 | Eingeleitet | Jefferies | Buy |
2021-12-03 | Eingeleitet | BofA Securities | Buy |
2021-11-22 | Hochstufung | JP Morgan | Neutral → Overweight |
2021-05-18 | Eingeleitet | UBS | Neutral |
2021-05-10 | Hochstufung | Wedbush | Neutral → Outperform |
2021-04-26 | Fortgesetzt | Credit Suisse | Outperform |
2021-02-10 | Herabstufung | Wedbush | Outperform → Neutral |
2020-12-15 | Fortgesetzt | H.C. Wainwright | Buy |
2020-12-11 | Bestätigt | Needham | Buy |
2020-10-23 | Eingeleitet | Cantor Fitzgerald | Overweight |
2020-09-29 | Fortgesetzt | JP Morgan | Neutral |
2020-09-29 | Eingeleitet | Needham | Buy |
2019-12-18 | Eingeleitet | Wedbush | Outperform |
2019-11-12 | Eingeleitet | BTIG Research | Buy |
2019-10-25 | Eingeleitet | H.C. Wainwright | Buy |
2019-07-15 | Eingeleitet | Canaccord Genuity | Buy |
2019-07-15 | Eingeleitet | Cowen | Outperform |
2019-07-15 | Eingeleitet | Credit Suisse | Outperform |
2019-07-15 | Eingeleitet | JP Morgan | Overweight |
Alle ansehen
Stoke Therapeutics Inc Aktie (STOK) Neueste Nachrichten
What analysts say about Stoke Therapeutics Inc. stockRapid growth opportunities - jammulinksnews.com
Why Stoke Therapeutics Inc. stock attracts strong analyst attentionProven Return Strategy Execution - Newser
Biogen Inc. (BIIB) Partners with Stoke Therapeutics to Tackle Dravet Syndrome - MSN
Published on: 2025-07-22 13:02:52 - jammulinksnews.com
Stoke Therapeutics Inc. Stock Analysis and ForecastUnprecedented profit potential - jammulinksnews.com
What drives Stoke Therapeutics Inc. stock priceRecord-setting profit potential - Autocar Professional
Is Stoke Therapeutics Inc. a good long term investmentExceptional profit velocity - PrintWeekIndia
Jefferies Financial Group Begins Coverage on Stoke Therapeutics (NASDAQ:STOK) - Defense World
How to Take Advantage of moves in (STOK) - news.stocktradersdaily.com
Is Stoke Therapeutics, Inc.'s (NASDAQ:STOK) Recent Stock Performance Influenced By Its Fundamentals In Any Way? - 富途牛牛
Stoke Therapeutics, Inc.'s (NASDAQ:STOK) Stock On An Uptrend: Could Fundamentals Be Driving The Momentum? - simplywall.st
Stoke Therapeutics (STOK): A High-Conviction Buy with Disease-Modifying Potential in Dravet Syndrome - AInvest
Jefferies Recommends Stoke Therapeutics (STOK) with a Buy Rating - GuruFocus
Jefferies initiates Stoke Therapeutics stock with Buy rating on epilepsy drug potential - Investing.com Canada
Published on: 2025-07-18 11:35:29 - jammulinksnews.com
Stoke Therapeutics’ EMPEROR Study: A New Hope for Dravet Syndrome - TipRanks
Stoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)July 16, 2025 - BioSpace
Analysts Are Bullish on Top Healthcare Stocks: Eli Lilly & Co (LLY), Stoke Therapeutics (STOK) - The Globe and Mail
How Stoke Therapeutics Inc. stock performs during market volatilityProven Trading Plan - Newser
What makes Stoke Therapeutics Inc. stock price move sharplyDaily Price Surge List - Newser
Stoke Therapeutics (NASDAQ:STOK) investors are sitting on a loss of 58% if they invested five years ago - Yahoo Finance
Canaccord Genuity Keeps Their Buy Rating on Stoke Therapeutics (STOK) - The Globe and Mail
Case builds for Biogen, Stoke's Dravet syndrome drug - pharmaphorum
Biogen and Stoke Therapeutics Announce Presentation of Data from Studies of Zorevunersen, an Investigational Medicine for Dravet syndrome, at the 16th European Paediatric Neurology Society (EPNS) Congress - Ariva
Biogen (BIIB) Presents Promising Data from Zorevunersen Studies - GuruFocus
Revolutionary Dravet Syndrome Treatment: Biogen's Zorevunersen Delivers Cognitive Gains in Phase 3 Trial - Stock Titan
Finanzdaten der Stoke Therapeutics Inc-Aktie (STOK)
Umsatz
Nettogewinn
Free Cashflow
ENV
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):